Altimmune, Inc. ALT
$2.63
▲ +0.77% 24H
About
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based therapeutics for obesity, metabolic diseases, and liver diseases. Its lead product candidate, pemvidutide, is a novel GLP-1/glucagon dual receptor agonist designed to address obesity and metabolic dysfunction-associated steatohepatit…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees59
TickerALT
Statistics
Market Cap$343.1M
Revenue (TTM)$41000
Net Income-$88.1M
Net Margin-214861.0%
EPS$-1.00
P/E-2.59
P/S14099.38
P/B1.20
EV/EBITDA-2.21
ROE-42.7%
Dividend Yield—
Price$2.63
Data: Twelve Data · Revenue = mcap / P/S